市場調查報告書
商品編碼
1347759
2023-2028 年按治療、癌症類型(非小細胞肺癌、小細胞肺癌)、配銷通路和地區分類的肺癌治療市場報告Lung Cancer Therapeutics Market Report by Therapy, Cancer Type (Non-small Cell Lung Cancer, Small Cell Lung Cancer ), Distribution Channel, and Region 2023-2028 |
2022年,全球肺癌治療市場規模達到272.216億美元。展望未來,IMARC Group預計到2028年該市場將達到502.33億美元,2023-2028年年複合成長率(CAGR)為10.90%。由於不健康的生活方式和過度吸煙,肺癌患病率不斷上升,個人對早期診斷和治療重要性的認知不斷提高,以及精準醫學的進步是推動市場的一些關鍵因素。
肺癌治療是指用於控制和治療肺癌症狀的各種治療方案,包括呼吸短促、胸痛、喘息和咳血。其中包括有助於減少和破壞肺部癌性腫瘤生長的藥物和手術。它們還涉及針對癌細胞特定基因突變或改變並刺激免疫系統對抗疾病的療法。目前,由於吸煙產品消費的增加、污染程度的上升以及不健康的飲食模式,肺癌患病率不斷上升,這促進了對有效肺癌治療方法的需求。
目前,人們對癌症早期診斷和治療益處的認知不斷提高,這是提供良好市場前景的關鍵因素之一。除此之外,提供個性化治療選擇並改善患者治療效果的靶向療法的開發也有利於市場成長。分子測試和基因分析能夠識別肺癌細胞中的特定突變和生物標記。與此相一致的是,擴大使用奈米藥物,通過增強療效和減少副作用來提高抗癌藥物向受影響組織的有效遞送。此外,擴大使用免疫檢查點抑製劑(ICIs)作為單一療法或與其他療法聯合使用,正在創造積極的市場前景。此外,聯合療法(涉及同時使用多種治療方式)的日益普及正在加強市場成長。除此之外,液體活體組織切片的廣泛使用正在推動市場的發展,液體活體組織切片涉及血液樣本中循環腫瘤脫氧核糖核酸(DNA)和其他生物標記的分析。液體活體組織切片是一種評估腫瘤突變狀態和治療反應的非侵入性方法,從而能夠即時監測和調整治療。此外,製藥公司、研究機構和醫療保健提供者之間開發創新療法和藥物的戰略合作正在推動市場成長。與此同時,肺癌新型治療方式、藥物輸送系統和診斷工具的持續研究和技術進步預計將刺激市場成長。
The global lung cancer therapeutics market size reached US$ 27,221.60 Million in 2022. Looking forward, IMARC Group expects the market to reach US$ 50,233 Million by 2028, exhibiting a growth rate (CAGR) of 10.90% during 2023-2028. The rising prevalence of lung cancer due to unhealthy lifestyles and excessive smoking, increasing awareness among individuals about the importance of early diagnosis and treatment, and advancements in precision medicine represent some of the key factors driving the market.
Lung cancer therapeutics refer to various treatment options used for managing and treating the symptoms of lung cancer, which include shortness of breath, chest pain, wheezing, and coughing up blood. They include medications and surgery that help reduce and destroy the growth of cancerous tumors in the lungs. They also involve therapies that focus on specific genetic mutations or alterations in cancer cells and stimulate the immune system to fight against the disease. At present, the growing prevalence of lung cancer on account of the increasing consumption of smoking products, rising pollution level, and unhealthy dietary patterns is catalyzing the demand for effective lung cancer therapeutics.
The rising awareness among individuals about the benefits of early diagnosis and treatment of cancer currently represents one of the key factors offering a favorable market outlook. Apart from this, the development of targeted therapies that offer personalized treatment options and improve patient outcomes are favoring market growth. Molecular testing and genetic profiling enable the identification of specific mutations and biomarkers in lung cancer cells. In line with this, the increasing use of nanomedicine to increase the efficient delivery of the anticancer drug to the affected tissues by enhancing the efficacy and reducing the side effects. Furthermore, the increasing use of immune checkpoint inhibitors (ICIs) as monotherapy or in combination with other therapies is creating a positive market outlook. Additionally, the rising adoption of combination therapies, which involve the simultaneous use of multiple treatment modalities, is strengthening the market growth. Besides this, the expanding utilization of liquid biopsies, which involve the analysis of circulating tumor deoxyribonucleic acid (DNA) and other biomarkers in blood samples, is driving the market. Liquid biopsies act as a non-invasive method of assessing tumor mutational status and treatment response, thereby enabling real-time monitoring and adjustment of therapy. Moreover, strategic collaborations between pharmaceutical companies, research institutions, and healthcare providers to develop innovative therapies and drugs are propelling market growth. Along with this, ongoing research and technological advancements in novel treatment modalities, drug delivery systems, and diagnostic tools for lung cancer are expected to stimulate market growth.
IMARC Group provides an analysis of the key trends in each segment of the global lung cancer therapeutics market, along with forecasts at the global, regional, and country levels from 2023-2028. Our report has categorized the market based on therapy, cancer type, and distribution channel.
Targeted Therapy
Bevacizumab
Dabrafenib/Trametinib
Erlotinib Hydrochloride
Osimertinib
Others
Immunotherapy
Durvalumab
Nivolumab
Atezolizumab
Pembrolizumab
Radiation Therapy
External Beam
Internal Beam
Systemic
Chemotherapy
The report has provided a detailed breakup and analysis of the lung cancer therapeutics market based on the therapy. This includes targeted therapy (bevacizumab, dabrafenib/trametinib, erlotinib hydrochloride, Osimertinib and others); immunotherapy (durvalumab, nivolumab, atezolizumab and pembrolizumab); radiation therapy (external beam, internal beam and systemic); and chemotherapy. According to the report, targeted therapy represented the largest segment.
Non-small Cell Lung Cancer (NSCLC)
Small Cell Lung Cancer (SCLC)
A detailed breakup and analysis of the lung cancer therapeutics market based on the cancer type has also been provided in the report. This includes non-small cell lung cancer (NSCLC), and small cell lung cancer (SCLC). According to the report, non-small cell lung cancer (NSCLC) accounted for the largest market share.
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Others
The report has provided a detailed breakup and analysis of the lung cancer therapeutics market based on the distribution channel. This includes hospital pharmacies, retail pharmacies, online pharmacies, and others. According to the report, hospital pharmacies represented the largest segment.
North America
United States
Canada
Asia-Pacific
China
Japan
India
South Korea
Australia
Indonesia
Others
Europe
Germany
France
United Kingdom
Italy
Spain
Russia
Others
Latin America
Brazil
Mexico
Others
Middle East and Africa
The report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, North America was the largest market for lung cancer therapeutics. Some of the factors driving the North America lung cancer therapeutics market included the increasing prevalence of lung cancer, rising awareness among individuals about the benefits of early diagnosis and treatment, technological advancements in treatment procedures, etc.
The report has also provided a comprehensive analysis of the competitive landscape in the global lung cancer therapeutics market. Detailed profiles of all major companies have been provided. Some of the companies covered include AbbVie Inc., Amgen Inc., AstraZeneca Plc, Boehringer Ingelheim International GmbH, Bristol-Myers Squibb Company, Daiichi Sankyo Company Limited, Eli Lilly and Company, GSK PLC, Merck & Co. Inc., Novartis AG, Pfizer Inc., Roche Holding AG, Takeda Pharmaceutical Company Limited, etc. Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.
Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.